Clinical Trial Update: Reversal of Moderate or Superficial Neuromuscular Blockade Induced by Cisatracurium [Phase 4]

View source ↗

Summary

Phase 4 trial updating on reversal of moderate or superficial neuromuscular blockade induced by cisatracurium.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle Weakness

Drugs mentioned

• Cisatracurium (Cisatracurium besylate)
• Neostigmine (neostigmine)

Snippet

Sponsor: Pontificia Universidade Catolica de Sao Paulo | Conditions: Neostigmine, Neuromuscular Blocking Agents | Phase 4 | Status: COMPLETED